Free Trial
→ I was wrong about Trump (From Porter & Company) (Ad)
NYSE:OGEN

Oragenics 11/9/2023 Earnings Report

Oragenics logo
$1.39 -0.04 (-2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.39 +0.00 (+0.29%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Oragenics EPS Results

Actual EPS
-$25.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Date
11/9/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116417/0/en/oragenics-inc-announces-u-s-based-drug-manufacturing-agreement-to-support-onp-002-clinical-development.html
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking Alpha
July 3, 2025  |  seekingalpha.comhttps://seekingalpha.com/pr/20153329-oragenics-inc-announces-pricing-of-public-offering-of-up-to-20-million-of-preferred-stock-and
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
July 25 at 2:00 AM  |  Porter & Company (Ad)
Oragenics stock tumbles after announcing $20 million preferred stock offering
July 2, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/oragenics-stock-tumbles-after-announcing-20-million-preferred-stock-offering-93CH-4119646
Oragenics Completes Approximately $16.5 Million Offering
July 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/02/3109534/0/en/oragenics-completes-approximately-16-5-million-offering.html
Oragenics shares plunge following announcement of $20 million preferred stock sale
July 1, 2025  |  msn.comhttps://www.msn.com/en-us/general/general/oragenics-shares-plunge-following-announcement-of-20-million-preferred-stock-sale/ar-AA1HLPPB
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSE:OGEN), a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

View Oragenics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles